Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 18.66 0.32% 0.06
HALO closed up 0.32 percent on Wednesday, April 25, 2018, on 60 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 10

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical HALO trend table...

Date Alert Name Type % Chg
Apr 25 Bollinger Band Squeeze Range Contraction 0.00%
Apr 25 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Apr 25 Lower Bollinger Band Touch Weakness 0.00%
Apr 25 Oversold Stochastic Weakness 0.00%
Apr 24 Bollinger Band Squeeze Range Contraction 0.32%
Apr 24 Stochastic Reached Oversold Weakness 0.32%
Apr 24 BB Squeeze + Lower Band Touch Range Contraction 0.32%
Apr 24 Lower Bollinger Band Touch Weakness 0.32%
Apr 24 Oversold Stochastic Weakness 0.32%
Apr 23 Spinning Top Other -1.06%

Older signals for HALO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.48
52 Week Low 11.41
Average Volume 889,389
200-Day Moving Average 17.3722
50-Day Moving Average 19.6019
20-Day Moving Average 19.2375
10-Day Moving Average 19.177
Average True Range 0.6011
ADX 15.7
+DI 14.74
-DI 26.75
Chandelier Exit (Long, 3 ATRs ) 18.1967
Chandelier Exit (Short, 3 ATRs ) 20.1333
Upper Bollinger Band 19.9866
Lower Bollinger Band 18.4884
Percent B (%b) 0.11
BandWidth 7.787914
MACD Line -0.2295
MACD Signal Line -0.1489
MACD Histogram -0.0807
Fundamentals Value
Market Cap 2.5 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -20.06
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.35
Resistance 3 (R3) 19.32 19.05 19.24
Resistance 2 (R2) 19.05 18.88 19.07 19.20
Resistance 1 (R1) 18.86 18.77 18.96 18.89 19.16
Pivot Point 18.59 18.59 18.64 18.61 18.59
Support 1 (S1) 18.40 18.42 18.50 18.43 18.16
Support 2 (S2) 18.13 18.31 18.15 18.12
Support 3 (S3) 17.94 18.13 18.09
Support 4 (S4) 17.97